Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Zhi-Cheng JinBin-Yan ZhongJian-Jian ChenHai-Dong ZhuJun-Hui SunGuo-Wen YinNai-Jian GeBiao LuoWen-Bin DingWen-Hui LiLi ChenYu-Qing WangXiao-Li ZhuWei-Zhu YangHai-Liang LiGao-Jun Tengnull nullPublished in: European radiology (2023)
• This propensity score-matched study demonstrates that TACE plus immunotherapy and molecular targeted therapy have a longer OS, PFS, and ORR compared with TACE monotherapy in HCC. • Grade 3 or 4 adverse events occurred in 14/84 (16.7%) patients treated with TACE plus immunotherapy and molecular targeted therapy compared with 12/147 (8.2%) patients in the monotherapy group, while no grade 5 adverse events were observed in all cohorts.